Vittia (VITT3) Q3 2025 earnings summary

Executive summary

• Net revenue grew 5.0% year-over-year in 3Q25 to R$324.9 million and 5.8% in 9M25 to R$561.8 million, reflecting resilience in a challenging agribusiness environment with tight margins and limited credit.

• Adjusted EBITDA for 3Q25 was R$83.5 million (+0.4% vs. 3Q24), with a margin of 25.7%; adjusted net result for 9M25 was R$28.2 million (-2.7% vs. 9M24).

• Strong operating cash flow generation of R$105.9 million in 9M25, up 24.3% year-over-year, supporting disciplined leverage and financial stability.

• Strategic focus on innovation, with new biological product launches and expansion into Mexico, including 12 active registrations.

• Operational efficiency, cost rationalization, and disciplined credit management remained priorities.

Financial highlights

• Net revenue grew 5.0% in 3Q25 and 5.8% in 9M25 year-over-year; adjusted EBITDA reached R$83.5 million in 3Q25, with a margin of 25.7%.

• Gross margin declined to 32.2% in 3Q25 and 32.3% in 9M25, reflecting margin pressure from product mix.

• SG&A expenses represented 22.9% of net revenue in 9M25, a 1.8 p.p. decrease year-over-year.

• Investments (CAPEX) totaled R$24.5 million in 9M25 (-7.7% vs. 9M24), mainly for operational improvements.

• R$47.2 million paid in share buybacks and interest on capital in 9M25.

Outlook and guidance

• Management expects gradual normalization of sales in 4Q25 and early 1Q26, with positive prospects for the 2025/26 crop cycle.

• Continued focus on operational efficiency, portfolio diversification, and financial discipline to capture future opportunities.

• Expansion in Mexico and potential entry into the U.S. and broader Latin America markets.